Roth/MKM Downgrades LB Pharmaceuticals Inc (LBRX) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/5/2026
- Wall St set for muted open as tech stocks take a breather
- Oil slips on rise in Middle East crude exports and G7 stocks release
- Intel stock slides as TSMC explores Terafab tie-up, analyst flags share losses
- Schneider Electric to acquire PTC for $22.6 billion in all-cash deal
- Five things to watch in markets in the week ahead
Tweet
Share
E-mailGet Alerts LBRX Hot Sheet
Price: $36.25 -2%
Rating Summary:
9 Buy, 1 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 10 | Down: 13 | New: 25
Rating Summary:
9 Buy, 1 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 10 | Down: 13 | New: 25
Join SI Premium – FREE
Roth/MKM analyst Boobalan Pachaiyappan downgraded LB Pharmaceuticals Inc (NASDAQ: LBRX) from Buy to Neutral.
For an analyst ratings summary and ratings history on LB Pharmaceuticals Inc click here. For more ratings news on LB Pharmaceuticals Inc click here.
Shares of LB Pharmaceuticals Inc closed at $36.99 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Barrington Research Starts Banzai (PARA) at Market Perform
- Needham Reiterates Buy Rating on GE HealthCare (GEHC)
- UBS Reiterates Neutral Rating on Coca-Cola Europacific Partners (CCEP)
Create E-mail Alert Related Categories
DowngradesRelated Entities
Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
